Obesity as a Chronic Disease

Framing obesity as a chronic disease asserts three things: that excess adiposity impairs health, that body weight is physiologically defended rather than chosen, and that relapse on stopping treatment is the expected course rather than non-compliance. The American Medical Association adopted the disease designation in 2013, over the objection of its own science council, and the framing remains genuinely contested. A 2025 Lancet Diabetes and Endocrinology commission sharpened it by separating clinical obesity, defined by organ dysfunction, from preclinical obesity, where excess fat is a risk state only.

The evidence usually cited for chronicity is what happens on withdrawal. In the STEP 1 semaglutide extension, participants regained most of the lost weight within a year of stopping, cardiometabolic markers drifting back with it. On the benefit side, the SELECT trial in 2023 reported fewer major adverse cardiovascular events in people with overweight or obesity and established cardiovascular disease but no diabetes, the kind of hard-outcome result a disease model needs.

The framing decides practical questions. If obesity is chronic, treatment is indefinite and stopping predicts regain, which is an argument about insurance coverage, formulary duration and how relapse is discussed. If it is a risk factor, intermittent management is defensible and the bar for lifelong pharmacotherapy is higher.

The label gets stretched in both directions. It is used to imply that everyone above a BMI threshold has a disease needing drug treatment, which the BMI-only definition cannot support and the clinical versus preclinical split rejects. It is also dismissed wholesale as manufacturer messaging, which ignores the withdrawal and outcome data. A disease designation describes a condition; it does not by itself indicate treatment for a particular person.